SuMMiT-D
Research type
Research Study
Full title
Supporting people with type 2 diabetes in effective use of their medicine through a system comprising mobile health technology integrated with clinical care compared with usual care: a randomised controlled trial
IRAS ID
280928
Contact name
Andrew Farmer
Contact email
Sponsor organisation
University of Oxford
ISRCTN Number
ISRCTN15952379
Duration of Study in the UK
2 years, 1 months, 30 days
Research summary
SuMMiT-D: SUpport through Mobile Messaging and dIgital health Technology for Diabetes.
Type 2 diabetes is a lifelong condition that causes a person's blood sugar to become too high. In the UK, it affects more than 4 million people. It can cause serious long-term health problems. Medicines to lower blood glucose, blood pressure, and cholesterol, can stop complications developing, if taken as intended. However, people are often concerned about starting new medicines and face difficulties in taking them regularly.
SuMMiT-D has drawn on patients' experiences and suggestions, and previous research which has shown that text messages can be effective for some conditions. Based on these we have developed text messages that aim to encourage and support people with type 2 diabetes in taking their medication and managing their condition. The messages were put together by health psychologists and have been reviewed by patients.
The aim of this trial is to compare the effectiveness and cost effectiveness of brief text messaging to support patients with type 2 diabetes taking diabetes medicine (glucose, blood pressure or lipid lowering) in reducing risk factors for diabetes complications, with usual care.
958 patients with type 2 diabetes, ≥35 years of age, who are taking oral glucose lowering treatment, blood pressure lowering treatment or lipid lowering treatment (diabetes treatments) either alone or in combination, will be invited or approached by their healthcare team or may see trial promotional material. Interested people will contact the trial team to register their interest in taking part. Participants will be randomised to either tailored condition specific text messages or non-health related messages for 12 months following randomisation. They will be asked to complete questionnaires at baseline, 13-, 26-, and 52-weeks.
Notes reviews will be conducted at baseline, 12 months.
Up to 60 participants will also take part in qualitative interviews.REC name
West of Scotland REC 5
REC reference
20/WS/0103
Date of REC Opinion
25 Aug 2020
REC opinion
Favourable Opinion